⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Article retracted — Score invalidated
Article retracted
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin in 23 randomized clinical trials (3349 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries. The primary meta-analysis was carried out by excluding studies at a high risk of bias. Retracted due to inclusion of fraudulent trial data that distorted the findings.
Coeff. authors = avg(0.00, 0.00) = 0.00
Coeff. editorial = avg(0.00, 0.00) = 0.00
min(0.00, 0.00) = 0.00← lowest dominates
Alert signal : Retraction → Coefficient forced to 0
Article retracted
Alert signal : Retraction → Coefficient forced to 0
Article retracted
Final coefficient : 0.00
Final score = 0/100 × 0.00 × 100 = 0/100
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Horby P — 2020 · The New England journal of medicine
Contrasted resultsAdverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A …
Amanzio M — 2022 · Lancet Reg Health Eur
Contrasted resultsRemdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH — 2020 · The New England journal of medicine
Contrasted resultsCovid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
Andrews N — 2022 · The New England journal of medicine
Contrasted resultsSeverity of SARS-CoV-2 Reinfections as Compared with Primary Infections.
Abu-Raddad LJ — 2021 · The New England journal of medicine